Title :

Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.

Author(s) :

Laharie, David [Auteur]
Service d'Hépato-Gastro-Entérologie
Hôpital Haut-Lévêque [CHU Bordeaux]
D'haens, G. [Auteur]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lambrecht, G. [Auteur]
Bossuyt, P. [Auteur]
Bouhnik, Yoram [Auteur]
Louis, E. [Auteur]
Van Der Woude, C. J. [Auteur]
Buisson, Anthony [Auteur]
Service Hépato-Gastro-Entérologie [CHU Clermont-Ferrand]
CHU Clermont-Ferrand
Van Hootegem, P. [Auteur]
Allez, Matthieu [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Filippi, Jérôme [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Hôpital l'Archet
Brixi, Hedia [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Gilletta, Cyrielle [Auteur]
Service de Gastroentérologie et pancréatologie [CHU Toulouse]
Picon, Laurence [Auteur]
Centre Hospitalier Régional Universitaire de Tours [CHRU Tours]
Baert, F. [Auteur]
Vermeire, S. [Auteur]
Duveau, Nicolas [Auteur]
Centre Hospitalier de Roubaix
Peyrin-Biroulet, Laurent [Auteur]
Centre Hospitalier Universitaire de Nancy [CHU Nancy]

Journal title :

Clinical Gastroenterology and Hepatology

Abbreviated title :

Clin Gastroenterol Hepatol

Publication date :

2021-12-03

ISSN :

1542-7714

English keyword(s) :

Crohn's Disease
Deep Remission
Infliximab
Endoscopic Remission

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background & Aims Crohn's disease (CD) patients included in the Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) trial started infliximab in combination with an immunosuppressant for 1 year. The ...
Show more >Background & Aims Crohn's disease (CD) patients included in the Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) trial started infliximab in combination with an immunosuppressant for 1 year. The aim of the present study was to determine the long-term disease course beyond the study period. Methods We compared the outcomes of patients who did or did not reach the primary end point of the TAILORIX trial, defined as sustained corticosteroid-free clinical remission from weeks 22 through 54, with no ulcers on ileocolonoscopy at week 54. The primary outcome of this follow-up study was the progression-free survival of CD defined by anal or major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment. Results The 95 patients (median disease duration, 4.5 mo; interquartile range, 1.0–56.6 mo) analyzed, including 45 (47%) who achieved the primary end point, were followed up for a median duration of 64.2 months (interquartile range, 57.6–69.9 mo) after the end of the study period. There was no significant difference in CD progression-free survival at 1, 3, and 5 years between patients who achieved the TAILORIX primary end point and patients who did not (P = .64). No difference was observed between both groups for each component of CD progression: anal surgery, major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment. Conclusions Achieving a sustained clinical remission off steroids with complete endoscopic remission in this cohort of 95 patients with early CD was not associated with less disease progression. Prospective trials to define the therapeutic goals that change the natural history of CD and prevent complications are needed.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T05:34:31Z
2024-02-27T16:14:20Z